ADHEREX TECHNOLOGIES, INC. Patent applications |
Patent application number | Title | Published |
20120022083 | SMALL MOLECULE MODULATORS OF CELL ADHESION - Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: | 01-26-2012 |
20110130359 | METHODS FOR PREVENTING OR REDUCING NEUROTOXICITY ASSOCIATED WITH ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS - Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient. | 06-02-2011 |
20090291967 | SMALL MOLECULE MODULATORS OF CELL ADHESION - Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: | 11-26-2009 |
20090196833 | COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME - Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and/or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs. | 08-06-2009 |
20090131306 | CHEMICALLY MODIFIED CYCLIC PEPTIDES CONTAINING CELL ADHESION RECOGNITION (CAR) SEQUENCES AND USES THEREFOR - Chemically modified cyclic peptides comprising cell adhesion recognition (CAR) sequences are provided having improved properties, such as improved stability. Also provided are methods of making and using same. | 05-21-2009 |
20080255168 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS - Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient. Also provided are topical formulations comprising DPD, TP and/or UP inhibitors and methods of using same. | 10-16-2008 |